Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication associated with antiresorptive and antiangiogenic therapies, particularly bisphosphonates and denosumab. Its pathogenesis is multifactorial, involving suppression of bone remodeling, impaired angiogenesis, infection, and immune dysregulation, leading to delayed healing and necrotic bone exposure. Current management ranges from conservative therapy to surgical intervention, yet outcomes remain unpredictable and recurrence rates are significant. Platelet-rich fibrin (PRF), an autologous second-generation platelet concentrate, has gained attention as a regenerative adjunct due to its sustained release of growth factors and pro-angiogenic properties. This thesis reviews the biological mechanisms and clinical evidence supporting PRF use in MRONJ prevention and treatment. Available literature suggests that PRF may enhance mucosal healing, improve vascularization, and support bone regeneration, although further standardized clinical studies are required to confirm long-term effectiveness.